Not only are these gene candidates known to be transcriptionally upregulated by the coordinated activation of both NFκB and AP-1 [22-26], their overexpression has been linked to clinically aggressive forms of breast cancer and, in some cases, to tamoxifen resistance [28,47,48]. Here, FOSB is linked to breast carcinoma.